PENALTIES.

SEC. 103. PENALTIES. (a) Prohibited Acts.—Section 301 (21 U.S.C. 331) is amended by adding at the end the following: “(ccc)(1) The resale of a compounded drug that is labeled ‘not for resale’ in accordance with section 503B. “(2) With respect to a drug to be compounded pursuant to section 503A or 503B, the intentional falsification of a prescription, as applicable. “(3) The failure to report drugs or adverse events by an entity that is registered in accordance with subsection (b) of section 503B.” . (b) Misbranded Drugs.—Section 502 (21 U.S.C. 352) is amended by adding at the end the following: “(bb) If the advertising or promotion of a compounded drug is false or misleading in any particular.” .